Literature DB >> 807793

[Anticoagulant efficacy of Sintrom and blood concentration of Ludiomil on simultaneous administration of the two preparations].

F Michot, L Glaus, D B Jack, W Theobald.   

Abstract

As long-term anticoagulant therapy with coumarin derivates like Sintrom becomes more and more important the question arises whether there is an interaction with a new drug like Ludiomil. An open, noncomparative trial was carried out with 20 patients receiving Sintrom (overall mean :3.0 mg/d, range :0 to 10 mg/d) for a period of 4 weeks, and in addition, during the second and third week Ludiomil (50 mg t. i. d.) orally. As a measurement of the efficacy of the antiocoagulant therapy, the correlation coefficients between the doses of Sintrom and the prothrombin value of the nex day were calculated for each patient and each week separately. An analysis of variance did not show any statistically significant difference between the correlation coefficients of the weeks with and without Ludiomil therapy, i.e. there is no change in the efficacy of the anticoagulant therapy. During the Ludiomil therapy the control of the anticoagulant therapy was slightly better, i.e. the fluctuations of the prothrombin values less, but statistically these differences were not significant. The plasma levels of Ludiomil in these patients were similar to thse found previously in both depressed and healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807793

Source DB:  PubMed          Journal:  Med Klin        ISSN: 0025-8458


  2 in total

1.  Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma gamma-GT in patients receiving mianserin.

Authors:  H Kopera; H Schenk; S Stulemeijer
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

Review 2.  Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.